Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | GHSR | Q92847 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067685 | 1.00 | CYP2D6 (0.42) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3071289 | 0.90 | GHSR (0.46) | CYP2D6GHSR | |
| SCHEMBL3071292 | 0.90 | GHSR (0.46) | CYP2D6GHSR | |
| SCHEMBL3080280 | 0.90 | POLB (0.47) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3080277 | 0.90 | POLB (0.47) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3068382 | 0.88 | MEN1 (0.46) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3080112 | 0.88 | CYP2D6 (0.48) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3080117 | 0.88 | CYP2D6 (0.48) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL3068385 | 0.88 | MEN1 (0.46) | CYP2D6GHSRS1PR1POLBTP53 | |
| SCHEMBL13139372 | 0.88 | GHSR (0.41) | CYP2D6GHSRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951675-B1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-03-20 | — | — | EP | disclosed |
| US-7790745-B2 | Tetrahydroisoquinoline LXR Modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1951675-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007047991-A1 | TETRAHYDROISOQUINOLINE AS LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093523-A1 | Tetrahydroisoquinoline LXR modulators | NR1H2, NR1H3, NR1I2 | CYP2D6 1127/4885GHSR 351/4885S1PR1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.